Ketamine causes rapid and sustained antidepressant effects that last longer than its presence in the body. This is due to ketamine getting trapped and accumulating in NMDA receptors, causing prolonged neural inhibition. Manipulating brain activity can shorten or extend ketamine’s effects. Highlights: Ketamine continues blocking NMDA receptors for 24 hours despite rapid elimination from plasma …
Scientists and mental health researchers have long been collecting evidence to discover what causes depression. Their goal is to find a specific neurotransmitter or system that could be targeted to develop a new class of antidepressant medication that would be more effective for the masses, result in less side effects, and be considered safe. While …
NRX-1074 is a new antidepressant under development by the biotech company Naurex. It is this same company that has already been granted “fast track” status by the FDA for their intravenous antidepressant GLYX-13 – which shows significant promise. Naurex’s private stock has been steadily rising due to emergence of preliminary evidence suggesting that both of …
A new antidepressant chemically named “GLYX-13” was developed by the biotech company Naurex for individuals with treatment-resistant depression. It is currently in clinical trials as an antidepressant augmentation strategy, meaning it is used as an add-on to already approved treatments. However, most evidence would suggest that it works extremely well as a standalone treatment option. …